{"name":"Infan Industria Quimica Farmaceutica Nacional","slug":"infan-industria-quimica-farmaceutica-nacional","ticker":"","exchange":"","domain":"","description":"Infan Industria Quimica Farmaceutica Nacional is a pharmaceutical company focused on the development and production of specialty drugs. The company has a strong presence in the Brazilian market and is currently advancing its lead drug, Oral Aroeira, through Phase 3 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Oral Aroeira","genericName":"Oral Aroeira","slug":"oral-aroeira","indication":"Treatment-resistant depression","status":"phase_3"}]}],"pipeline":[{"name":"Oral Aroeira","genericName":"Oral Aroeira","slug":"oral-aroeira","phase":"phase_3","mechanism":"Oral Aroeira is a small molecule that targets the serotonin receptor.","indications":["Treatment-resistant depression"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxNQnZaOHUwbWFabkV0RFAwSE4tQjNxVG5pNnFGWjFiNHlnbGI5SjBUc1pJblMydnpYN3NoV25ZcGlpdmdLM25nM0JHZVB1dnNGOGpvQjlhZ1Z3SFdFQjFPYWk3TnItRXJHeXRpTXctS1Q3RG5KVjF5MGVWX1d6eXM4RE5leUVMY0MtWUtoV0ZWeHZTb0UwZUM4bG95RkFUS25NWHdSVEwwRVF1OHNocUxiQTJvandOZ0J5aHpjVWlVRGpmYXNnbGtEcUZUQXJnN1Jmd0QxTjlvSFJKS21OY2djaVRhR2R2bnFQRHNBXzB4eDhTX3JNdnM5MWYzNk1Gc3p2WXcwakpNZlAzT3IyZzZaRjFhRG9MUGo5ZnNKODhVNWI4UXdqYV9JTTMtSDQtVEJKWHBvRm5ldDlWczFxWEdYaw?oc=5","date":"2025-09-02","type":"pipeline","source":"PR Newswire UK","summary":"Clostridioides difficile Infection Market Forecasts by DelveInsight Signal Groundbreaking Growth at a CAGR of 13.5% in the 7MM during the Forecast Period (2025-2034) - PR Newswire UK","headline":"Clostridioides difficile Infection Market Forecasts by DelveInsight Signal Groundbreaking Growth at a CAGR of 13.5% in t","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}